207 related articles for article (PubMed ID: 24655303)
1. Antimicrobial stewardship of β-lactams in intensive care units.
Cotta MO; Roberts JA; Tabah A; Lipman J; Vogelaers D; Blot S
Expert Rev Anti Infect Ther; 2014 May; 12(5):581-95. PubMed ID: 24655303
[TBL] [Abstract][Full Text] [Related]
2. Impact of CLSI Breakpoint Changes on Microbiology Laboratories and Antimicrobial Stewardship Programs.
Heil EL; Johnson JK
J Clin Microbiol; 2016 Apr; 54(4):840-4. PubMed ID: 26791363
[TBL] [Abstract][Full Text] [Related]
3. Microbiological surveillance and antimicrobial stewardship minimise the need for ultrabroad-spectrum combination therapy for treatment of nosocomial infections in a trauma intensive care unit: an audit of an evidence-based empiric antimicrobial policy.
Ramsamy Y; Muckart DJ; Han KS
S Afr Med J; 2013 Mar; 103(6):371-6. PubMed ID: 23725954
[TBL] [Abstract][Full Text] [Related]
4. Targeted simplification versus antipseudomonal broad-spectrum beta-lactams in patients with bloodstream infections due to
López-Cortés LE; Rosso-Fernández C; Núñez-Núñez M; Lavín-Alconero L; Bravo-Ferrer J; Barriga Á; Delgado M; Lupión C; Retamar P; Rodríguez-Baño J;
BMJ Open; 2017 Jun; 7(6):e015439. PubMed ID: 28601833
[TBL] [Abstract][Full Text] [Related]
5. Breakpoints for extended-spectrum beta-lactamase-producing Enterobacteriacae: pharmacokinetic/pharmacodynamic considerations.
MacGowan A
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():166-8. PubMed ID: 18154541
[TBL] [Abstract][Full Text] [Related]
6. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
Burgess DS; Frei CR
J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial Stewardship Approaches in the Intensive Care Unit.
Doernberg SB; Chambers HF
Infect Dis Clin North Am; 2017 Sep; 31(3):513-534. PubMed ID: 28687210
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of beta-lactam nonsusceptible Gram-negative bacilli and use and interpretation of current susceptibility breakpoints: a survey of infectious disease physicians.
Kallen AJ; Beekmann SE; Limbago B; Lentnek AL; Polgreen PM; Patel J; Srinivasan A
Diagn Microbiol Infect Dis; 2011 Nov; 71(3):316-9. PubMed ID: 21899980
[TBL] [Abstract][Full Text] [Related]
9. Prolonged infusions of β-lactam antibiotics: implication for antimicrobial stewardship.
George JM; Towne TG; Rodvold KA
Pharmacotherapy; 2012 Aug; 32(8):707-21. PubMed ID: 23307519
[TBL] [Abstract][Full Text] [Related]
10. beta-Lactams without a suicide inhibitor.
Giamarellou H
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():194-7. PubMed ID: 18154547
[TBL] [Abstract][Full Text] [Related]
11. [New beta-lactamases in enterobacteriaceae. The Danish Society of Clinical Microbiology].
Hansen DS
Ugeskr Laeger; 2006 Mar; 168(12):1228. PubMed ID: 16571319
[No Abstract] [Full Text] [Related]
12. Emergence and risk factors of β-lactamase-mediated resistance to oxyimino-β-lactams in Enterobacteriaceae isolates.
Manageiro V; Ferreira E; Jones-Dias D; Louro D; Pinto M; Diogo J; Caniça M
Diagn Microbiol Infect Dis; 2012 Mar; 72(3):272-7. PubMed ID: 22209509
[TBL] [Abstract][Full Text] [Related]
13. Extended-spectrum beta-lactamases: implications for the clinical laboratory and therapy.
Harada S; Ishii Y; Yamaguchi K
Korean J Lab Med; 2008 Dec; 28(6):401-12. PubMed ID: 19127103
[TBL] [Abstract][Full Text] [Related]
14. Reevaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for 9 beta-lactams: adjustments of breakpoints for strains producing extended spectrum beta-lactamases.
Jones RN; Craig WA; Ambrose PG; Dudley MN; Pottumarthy S
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):235-46. PubMed ID: 16105568
[TBL] [Abstract][Full Text] [Related]
15. Prolonged administration of β-lactam antibiotics - a comprehensive review and critical appraisal.
Osthoff M; Siegemund M; Balestra G; Abdul-Aziz MH; Roberts JA
Swiss Med Wkly; 2016; 146():w14368. PubMed ID: 27731492
[TBL] [Abstract][Full Text] [Related]
16. Impact of de-escalation of beta-lactam antibiotics on the emergence of antibiotic resistance in ICU patients: a retrospective observational study.
De Bus L; Denys W; Catteeuw J; Gadeyne B; Vermeulen K; Boelens J; Claeys G; De Waele JJ; Decruyenaere J; Depuydt PO
Intensive Care Med; 2016 Jun; 42(6):1029-39. PubMed ID: 27025939
[TBL] [Abstract][Full Text] [Related]
17. Extended-spectrum beta-lactamase-producing organisms.
Falagas ME; Karageorgopoulos DE
J Hosp Infect; 2009 Dec; 73(4):345-54. PubMed ID: 19596491
[TBL] [Abstract][Full Text] [Related]
18. [Enterobacteriaceae and beta-lactams : wild susceptibility patterns].
Philippon A; Arlet G
Pathol Biol (Paris); 2012 Apr; 60(2):112-26. PubMed ID: 22280847
[TBL] [Abstract][Full Text] [Related]
19. Novel plasmid-mediated beta-lactamases in enterobacteriaceae: emerging problems for new beta-lactam antibiotics.
Thomson KS; Prevan AM; Sanders CC
Curr Clin Top Infect Dis; 1996; 16():151-63. PubMed ID: 8714252
[No Abstract] [Full Text] [Related]
20. In vitro susceptibilities of clinical isolates of ertapenem-non-susceptible Enterobacteriaceae to nemonoxacin, tigecycline, fosfomycin and other antimicrobial agents.
Hsu MS; Liao CH; Liu CY; Yang CJ; Huang YT; Hsueh PR
Int J Antimicrob Agents; 2011 Mar; 37(3):276-8. PubMed ID: 21269811
[No Abstract] [Full Text] [Related]
[Next] [New Search]
